Literature DB >> 29795435

Prevention of relapse after allogeneic hematopoietic cell transplantation by donor and cell source selection.

Katharina Fleischhauer1,2, Katharine C Hsu3,4,5, Bronwen E Shaw6.   

Abstract

Allogeneic hematopoietic cell transplantation (HCT) is the most established form of cancer immunotherapy and has been successfully applied for the treatment and cure of otherwise lethal neoplastic blood disorders. Cancer immune surveillance is mediated to a large extent by alloreactive T and natural killer (NK) cells recognizing genetic differences between patient and donor. Profound insights into the biology of these effector cells has been obtained over recent years and used for the development of innovative strategies for intelligent donor selection, aiming for improved graft-versus-leukemia effect without unmanageable graft-versus-host disease. The cellular composition of the stem cell source plays a major role in modulating these effects. This review summarizes the current state-of the-art of donor selection according to HLA, NK alloreactivity and stem cell source.

Entities:  

Mesh：

Year:  2018        PMID： 29795435      PMCID： PMC7286200          DOI： 10.1038/s41409-018-0218-1

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


  99 in total

1.  KIR typing by non-sequencing methods: polymerase-chain reaction with sequence-specific primers.

Authors:  David Ordóñez; Manuela Moraru; Natalia Gómez-Lozano; Elisa Cisneros; Carlos Vilches
Journal:  Methods Mol Biol       Date:  2012

Review 2.  T-cell allorecognition: a case of mistaken identity or déjà vu?

Authors:  Julia K Archbold; Whitney A Macdonald; Scott R Burrows; Jamie Rossjohn; James McCluskey
Journal:  Trends Immunol       Date:  2008-04-18       Impact factor: 16.687

Review 3.  Selecting the best haploidentical donor.

Authors:  Shannon R McCurdy; Ephraim J Fuchs
Journal:  Semin Hematol       Date:  2016-08-15       Impact factor: 3.851

4.  Donor activating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hematopoietic stem cell transplantation.

Authors:  Jeffrey M Venstrom; Ted A Gooley; Stephen Spellman; James Pring; Mari Malkki; Bo Dupont; Effie Petersdorf; Katharine C Hsu
Journal:  Blood       Date:  2010-02-01       Impact factor: 22.113

Review 5.  Modern approaches to HLA-haploidentical blood or marrow transplantation.

Authors:  Christopher G Kanakry; Ephraim J Fuchs; Leo Luznik
Journal:  Nat Rev Clin Oncol       Date:  2015-08-25       Impact factor: 66.675

6.  Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation.

Authors:  Joseph Pidala; Stephanie J Lee; Kwang Woo Ahn; Stephen Spellman; Hai-Lin Wang; Mahmoud Aljurf; Medhat Askar; Jason Dehn; Marcelo Fernandez Viña; Alois Gratwohl; Vikas Gupta; Rabi Hanna; Mary M Horowitz; Carolyn K Hurley; Yoshihiro Inamoto; Adetola A Kassim; Taiga Nishihori; Carlheinz Mueller; Machteld Oudshoorn; Effie W Petersdorf; Vinod Prasad; James Robinson; Wael Saber; Kirk R Schultz; Bronwen Shaw; Jan Storek; William A Wood; Ann E Woolfrey; Claudio Anasetti
Journal:  Blood       Date:  2014-08-26       Impact factor: 22.113

7.  CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.

Authors:  Matthias Edinger; Petra Hoffmann; Joerg Ermann; Kathryn Drago; C Garrison Fathman; Samuel Strober; Robert S Negrin
Journal:  Nat Med       Date:  2003-08-17       Impact factor: 53.440

8.  The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy.

Authors:  Craig Kollman; Stephen R Spellman; Mei-Jie Zhang; Anna Hassebroek; Claudio Anasetti; Joseph H Antin; Richard E Champlin; Dennis L Confer; John F DiPersio; Marcelo Fernandez-Viña; Robert J Hartzman; Mary M Horowitz; Carolyn K Hurley; Chatchada Karanes; Martin Maiers; Carlheinz R Mueller; Miguel-Angel Perales; Michelle Setterholm; Ann E Woolfrey; Neng Yu; Mary Eapen
Journal:  Blood       Date:  2015-11-02       Impact factor: 22.113

9.  Copy number variation leads to considerable diversity for B but not A haplotypes of the human KIR genes encoding NK cell receptors.

Authors:  Wei Jiang; Chris Johnson; Jyothi Jayaraman; Nikol Simecek; Janelle Noble; Miriam F Moffatt; William O Cookson; John Trowsdale; James A Traherne
Journal:  Genome Res       Date:  2012-09-04       Impact factor: 9.043

10.  Development of a novel multiplex PCR assay to detect functional subtypes of KIR3DL1 alleles.

Authors:  Jeanette E Boudreau; Jean-Benoît Le Luduec; Katharine C Hsu
Journal:  PLoS One       Date:  2014-06-11       Impact factor: 3.240
View more
  3 in total

Review 1.  Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.

Authors:  Ying-Jun Chang; Xiang-Yu Zhao; Xiao-Jun Huang
Journal:  Front Immunol       Date:  2018-12-21       Impact factor: 7.561

Review 2.  Granulocyte Colony-Stimulating Factor-Primed Unmanipulated Haploidentical Blood and Marrow Transplantation.

Authors:  Ying-Jun Chang; Xiang-Yu Zhao; Xiao-Jun Huang
Journal:  Front Immunol       Date:  2019-11-01       Impact factor: 7.561

3.  Patient-based prediction algorithm of relapse after allo-HSCT for acute Leukemia and its usefulness in the decision-making process using a machine learning approach.

Authors:  Kyoko Fuse; Shun Uemura; Suguru Tamura; Tatsuya Suwabe; Takayuki Katagiri; Tomoyuki Tanaka; Takashi Ushiki; Yasuhiko Shibasaki; Naoko Sato; Toshio Yano; Takashi Kuroha; Shigeo Hashimoto; Tatsuo Furukawa; Miwako Narita; Hirohito Sone; Masayoshi Masuko
Journal:  Cancer Med       Date:  2019-07-15       Impact factor: 4.452
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.